Recently, the antibody Sacituzumab targeting the TROP-2 pathway in triple-negative breast cancer was approved expanding the targeted antibody treatment options beyond HER2 dependent breast cancers [63,64]. This evidence concerns the gene ERBB2 and breast cancer.